Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

NCT01522469 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Interventions

DRUG: Crenolanib Besylate (CP-868,596-26)

Sponsor

Arog Pharmaceuticals, Inc.